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Abstract
CDP-ME kinase (IspE) contributes to the non-mevalonate or deoxy-xylulose phosphate (DOXP) pathway for isoprenoid
precursor biosynthesis found in many species of bacteria and apicomplexan parasites. IspE has been shown to be essential
by genetic methods and since it is absent from humans it constitutes a promising target for antimicrobial drug
development. Using in silico screening directed against the substrate binding site and in vitro high-throughput screening
directed against both, the substrate and co-factor binding sites, non-substrate-like IspE inhibitors have been discovered and
structure-activity relationships were derived. The best inhibitors in each series have high ligand efficiencies and favourable
physico-chemical properties rendering them promising starting points for drug discovery. Putative binding modes of the
ligands were suggested which are consistent with established structure-activity relationships. The applied screening
methods were complementary in discovering hit compounds, and a comparison of both approaches highlights their
strengths and weaknesses. It is noteworthy that compounds identified by virtual screening methods provided the controls
for the biochemical screens.
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Introduction
Isoprenoids constitute one of the largest groups of natural
product compounds. They are structurally diverse and include
cannabinoids, essential oils, sterols, the prenyl groups of
chlorophyll and RNA among others. Isoprenoids are involved in
respiration, hormone-based signalling, the post-translational
processes that control lipid biosynthesis, meiosis, apoptosis,
glycoprotein biosynthesis, and protein degradation. Furthermore,
they represent important structural components of cell membranes
[1,2,3].
All isoprenoids are synthesised from two simple precursors,
isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate
(DMAPP). The precursors are provided by two distinct biosyn-
thetic pathways, which are distributed in an organism specific
manner. In mammals, the plant cytosol, certain bacteria and
trypanosomatids, these compounds are products of the mevalonate
(MVA) pathway. In most eubacteria, algae, chloroplasts, cyano-
bacteria and apicomplexan parasites the deoxy-xylulose phosphate
(DOXP) pathway (also called the non-mevalonate pathway)
generates IPP and DMAPP (Figure 1) [4,5,6,7].
This biosynthetic route to isoprenoid precursors is an essential
aspect of metabolism and the DOXP pathway is a genetically
validated target for broad-spectrum antimicrobial drugs against
malaria, tuberculosis, and a range of sexually transmitted
conditions [8]. The absence of this pathway in humans makes it
a particular attractive target for antimicrobial drug discovery.
Chemical validation is provided by the anti-malarial compound
fosmidomycin, which inhibits 1-deoxy-D-xylulose 5-phosphate
reductoisomerase (IspC, Figure 1) [9]. We have turned our
attention to another enzyme in the pathway, 4-diphosphocytidyl-
2C-methyl-D-erythritol (CDP-ME) kinase (IspE, Figure 1).
IspE catalyses the transfer of the ATP c-phosphate to 4-
diphosphocytidyl-2C-methyl-d-erythritol (CDP-ME) forming 4-
diphosphocytidyl-2C-methyl-d-erythritol 2-phosphate (CDP-
ME2P) and ADP. The gene encoding IspE has been shown to
be essential for survival in Escherichia coli, Bacillus subtilis,
Haemophilus influenzae, and Mycobacterium tuberculosis
[10,11,12,13,14,15]. Crystal structures of IspE from Aquifex aeolicus
(AaIspE), E. coli, Thermus thermophilus and M. tuberculosis have been
determined [16,17,18,19,20,21]. Our recent work has concentrat-
ed on AaIspE since it is a soluble, stable enzyme for which
reproducible protein crystals can be obtained [16,17,18]. AaIspE
has been co-crystallised with substrate and a non-hydrolysable
ATP derivative (AMP-PNP) and also inhibitors that are structur-
ally related to the substrate [18]. The cytidine moiety of the
substrate binds in a well-defined pocket and forms hydrogen bonds
with Lys145 and His25, p-stacking interactions with Tyr175 and
edge-face interactions with Tyr24 (AaIspE numbering, Figure 2).
The binding of the co-factor by IspE is unusual. Generally, ATP
binds to kinases with the purine moiety in anti conformation with
respect to the ribose. In contrast, in IspE, the energetically less
favourable syn conformation was found (Figure 3). Further, in a
typical protein kinase pocket the adenine moiety forms hydrogen
bonds with the backbone amide group of the so called hinge region
via N1, C2, and the exocyclic amino group [22]. In IspE, it is N1,
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35792N7, C8 and the exocyclic amino group that are involved in
hydrogen-bonds with surrounding amino acids. Despite these
differences, the typical donor–acceptor–donor motif found in
protein kinase inhibitors is still present in IspE (Figure 3).
Two types of IspE inhibitors are known. The majority of IspE
inhibitors mimic either the cytidine or phosphate-sugar moiety of
the substrate CDP-ME (Figure 4a–d) [16,17,18,23,24]. Crystal
structures of AaIspE in complex with cytidine analogues containing
a benzimidazole moiety attached to the ribose (Figure 4a and b)
have been determined suggesting that interactions in the cytidine
pocket are key for binding affinity [16]. Considering the size of
these molecules they are rather weak ligands for EcIspE with
affinities in the double-digit micromolar range. In contrast, the
smaller cytosine analogues (Figure 4c) bind more tightly to EcIspE
with some compounds of this series displaying IC50 values in the
low micromolar range [17,23]. Very recently, non-substrate like
EcIspE inhibitors have been reported [24]. The best characterized
compounds also have IC50 values in the low micromolar range
(Figure 4e and f). They were proposed to bind into the substrate
binding site forming stacking interactions with Tyr25 and Phe185
(Tyr24 and Tyr175 in AaIspE, Figure 2); however, the derived
structure-activity relationships (SAR) were not always consistent
with this binding mode as large changes to the presumably pi-
stacking moieties did not lead to large changes in affinity.
Motivated by the potential of IspE as a target for broad-
spectrum antimicrobial drugs we sought to discover non-substrate
like IspE inhibitors that can serve as starting points for the
development of new antimicrobials. There are several methods for
hit discovery. They can be divided into in silico and in vitro
approaches. [25,26,27]. Using both approaches, either lead-like or
fragment-like libraries can be screened. Lead-like libraries typically
Figure 1. Non-mevalonate pathway providing the isoprenoid precursors IPP and DMAPP.
doi:10.1371/journal.pone.0035792.g001
Figure 2. Substrate binding site of AaIspE (PDB code 2v2z). The
catalytic residues Lys9 and Asp130 are labelled together with other
residues important for ligand binding. The cytidine moiety of the
substrate forms hydrogen bonds with Lys145 and His25, p-stacking
interactions with Tyr175 and edge-face interactions with Tyr24.
doi:10.1371/journal.pone.0035792.g002
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fragment-like compounds which often leads to a higher hit rate
albeit frequently associated with weaker binding. If the structure of
the target is known, molecular docking is a viable in silico method
[28]. There are several studies that compare the outcomes of
docking and in vitro high-throughput screening
[29,30,31,32,33,34,35,36,37,38]. These studies suggest that often
the two methods identify different hit compounds. Reasons for this
are that as a result of virtual screening usually only few compounds
are tested experimentally which allows more robust assays to be
used and testing at higher concentrations which can identify
weaker inhibitors [29,31,32]. Further, much larger libraries can be
screened computationally than it is affordable to screen biochem-
ically [37]. On the other hand, due to shortcomings in docking
algorithms and scoring functions, potential hits might be missed
when only relying on computational methods [32,35,37,38]. To
benefit from the advantageous of these complementary strategies,
we decided to apply both for hit discovery for IspE.
The substrate and co-factor binding sites of IspE are highly
conserved across difference species. [16,18]. Therefore, in
principle, given the high level of conservation in IspE across
species either structure could serve as a template for structure-
based design of inhibitors with broad-spectrum antimicrobial
activity. However, since we had been able to reproducibly
crystallize and gain most crystallographic information with AaIspE
we decided to use the former for virtual screening. The intention
was then to determine crystal structures of new inhibitors in
complex with AaIspE. As A. aeolicus is a thermophilic organism
with the optimal temperature of AaIspE activity near 60uC [18]
and working at such elevated temperatures is not practical for a
biochemical screen, it was decided to use E. coli IspE (EcIspE) for
ligand binding characterisation. The high level of sequence
conservation provided confidence in this approach [18].
Here, we report on our hit discovery efforts for IspE. The crystal
structures were exploited for a structure-based ligand design
Figure 3. Superposition of adenine binding sites of human
CDK2 and AaIspE. ATP adopts the anti conformation in hCDK2 (PDB
code 2cch, carbon atoms coloured pink) while the ATP analogue AMP-
PNP adopts the syn conformation in AaIspE (PDB code 2v8p, carbon
atoms coloured light blue). Further, in hCDK2 adenine forms hydrogen
bonds with the backbone amide groups of the hinge region while in
AaIspE the backbone and side chain atoms of surrounding amino acids
are involved in hydrogen bonding-interactions. In both enzymes, a
donor-acceptor-donor motive (green circle) is important for molecular
recognition.
doi:10.1371/journal.pone.0035792.g003
Figure 4. Substrate-like (a–d) and non-substrate-like (e–f) IspE inhibitors together with inhibition values [16,17,18,23,24].
doi:10.1371/journal.pone.0035792.g004
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the cytidine-binding site. In addition, a biochemical screen of a
focussed compound library was carried out resulting in two
inhibitors with binding affinities in the low micromolar range. Hit
compounds from both approaches were expanded to compound
series. Compounds of these series have high ligand efficiencies [39]
($0.29 kcal/mol per non-hydrogen atom) and possess favourable
physico-chemical properties representing promising starting points
for the synthesis of new IspE inhibitors. In addition, we compared
the performance of in silico and in vitro screening and discuss their
strengths and weaknesses.
Results
Virtual screening for IspE inhibitors
Analysis of AaIspE crystal structures suggested that the cytidine
moiety plays a key role in ligand binding (Figure 2) [16]. The
cytidine binding site is formed by two aromatic amino acids (two
tyrosines in AaIspE and MtIspE, of which one is replaced by
phenylalanine in EcIspE) which form stacking and edge-face
interactions with the cytidine ring and a histidine residue that
stabilizes ligand binding by forming hydrogen bonds with N3 and
the exocyclic carbonyl and amino groups. This narrow cleft,
promoting aromatic and polar interactions, appears well suited to
accommodate small compounds based on scaffolds distinct from
cytidine with potential to display high ligand efficiency.
A hierarchical screening strategy was adopted to retrieve
fragments binding into the cytidine pocket of IspE (Figure 5).
First, a database of commercially available compounds was filtered
according to physico-chemical criteria. Next, a pharmacophore
hypothesis was derived and used to screen all compounds passing
the first filter step. The remaining compounds were docked into
the AaIspE binding site. Finally, the predicted binding modes were
post-filtered and promising compounds were short-listed for
purchase.
To derive a compound set for virtual screening, an in-house
virtual library containing 4,177,660 commercially available
compounds [40] was filtered by the following selection criteria:
at least one but not more than five hydrogen-bond donors, at least
one but not more than ten hydrogen-bond acceptors, at least nine
but not more than 23 heavy atoms and a clogP between 21 and 4.
In addition, the number of rotatable bonds was restricted to less
than seven, the total charge between 21 and +1, and at least one
but not more than two ring systems were allowed. Compounds
containing unwanted (e.g. reactive or potentially toxic) function-
alities were excluded. Only compounds that fulfilled all require-
ments (104,692) were taken to the next step.
The selected subset was further filtered using a protein-based
pharmacophore. When deriving the pharmacophore we aimed to
strike a reasonable balance between a complex query which
potentially retrieves very potent compounds but has only a very
low hit rate and a relaxed query retrieving many compounds
which prove not be active. To not be over descriptive we decided
to only include interactions to His25 (AaIspE numbering) which is
essential for recognition of the cytosine moiety of the substrate. In
all structures containing ligands interacting with this residue, ND
presumably carries a hydrogen atom to hydrogen bond with the
cytidine moiety of the ligands (Figure 2). However, in the crystal
structures His25 NE is solvent exposed and not involved in a
hydrogen-bonding network. Accordingly, it is possible that not ND
but NE carries a hydrogen atom when challenged with ligands
presenting a hydrogen-bond donor functionality. Therefore, both
states were considered in the derived pharmacophore. Further-
more, hydrogen-bond acceptor interactions to the backbone
amino group and hydrogen-bond donor interactions to the
carbonyl group of His25 were required (Figure 6). 42,912
compounds fulfilled at least two of these pharmacophore features.
Figure 5. Virtual screening cascade used to identify potential IspE inhibitors together with number of compounds that passed each
filter step.
doi:10.1371/journal.pone.0035792.g005
Figure 6. Structure-based pharmacophore for IspE inhibitors
considering the possible tautomers of His25. Either ND (a) or NE
(b) are carrying the hydrogen atom. Hydrogen-bond donor features and
their corresponding binding partners in the protein are shown in purple
and hydrogen-bond acceptor features and their corresponding binding
partners are coloured green.
doi:10.1371/journal.pone.0035792.g006
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the receptor and promising hits selected for testing. For this
purpose four different versions of the binding pocket were
prepared taking into account different tautomers of His25 and
the presence and absence of the co-factor. From each docking run,
the top 200 scoring molecules together with the top 200 scoring
molecules obtained when the score was divided by the number of
heavy atoms were stored in the final hit list. The latter was done to
favour small molecules which bind with a predicted high ligand
efficiency [39]. The resulting 1,600 docking poses were filtered for
compounds still in agreement with the described pharmacophore
hypothesis (Figure 6). Only 566 compounds fulfilled at least two
interactions required by the pharmacophore. By visual inspection
compounds with additional hydrogen-bonding or hydrophobic
interactions to the binding site were favoured and finally 14
compounds were purchased for evaluation. Five of these were
predicted to have interactions with His25 similar to those observed
for cytidine (Figure 6a) while nine compounds satisfied the
alternative arrangement of functional groups (Figure 6b).
Inhibition assays of shortlisted compounds
As explained, access to a body of accurate structural
information dictated that we use the AaIspE structure for the
virtual screening. However, A. aeolicus is a thermophilic organism
and the optimal temperature of AaIspE activity is near 60uC [18].
Therefore, we used EcIspE for ligand binding characterisation.
IC50 values could be determined for six compounds (Figure 7,
Table 1, and Figure 8a and b,). Their IC50 values were in the high
micromolar to low millimolar range with ligand efficiencies
ranging from 0.28 to 0.54 kcal/mol per non-hydrogen atom.
The most potent compound was 3 with an IC50 of 160 mM and a
ligand efficiency of 0.50 kcal/mol per non-hydrogen atom.
Biochemical screen of a focussed compound library
A focussed kinase-specific library consisting of 6,178 compounds
was available to us [40]. All library compounds contain a scaffold
capable of forming multiple hydrogen bonds with the hinge region
of typical serine/threonine protein kinases which is an important
recognition motif for ATP-competitive kinase inhibitors [22].
Despite structural differences between typical serine/threonine
protein kinase adenine binding sites and the IpsE adenine binding
site, both pockets require the same spatial distribution of
hydrogen-bond donors and acceptors (Figure 3). Furthermore,
one of the possible tautomers of the cytidine binding site is also
consistent with this pharmacophore (Figure 6b). Therefore,
screening this focussed kinase compound set seemed advanta-
geous.
The kinase library was screened in 384-well plates at 33 mM
compound concentration. In order to provide a standard inhibitor
for quality control a panel of typical protein kinase inhibitors, eg
staurosporine, purvalanol and kenpaullone was evaluated but
none of the compounds showed any EcIspE inhibition at 100 mM.
Therefore, compounds 3 and 4 (Table 1), which we identifed by
virtual screening were used to monitor the assay performance. An
average signal to noise ratio of 2.1 and an average Z9 value of 0.62
were obtained for the screen. Initial hits were re-assayed in
duplicate at the same concentrations as used for the primary
screen. This resulted in confirmed activity for two compounds
(Figure 9, Table 2, and Figure 8c and d). The compounds were
repurchased to determine their IC50 values. They inhibit EcIspE in
the low micromolar range (19 and 3 mM, respectively) and have
ligand efficiencies comparable to the virtual screening hits (0.29
and 0.35 kcal/mol per non-hydrogen atom, respectively).
Hit expansion and structure-activity relationships
Unfortunately, extensive co-crystallisation experiments and
soaking of preformed AaIspE crystals with the hits identified by
the virtual and high-throughput screening approaches did not
provide any structural information. Therefore, SAR for the virtual
screening hits were derived based on the modelled binding modes.
Only compounds with Hill coefficients close to one (3 and 4 in
Table 1) were followed up for hit expansion. Higher Hill
coefficients are not consistent with a binding model for competitive
binding to a single binding site and are possibly indicative of
compound aggregation, solubility issues, an assay artefact, or more
than a single class of binding sites in the assay solution [41,42,43].
The remaining compounds were therefore disregarded.
In the predicted binding mode, compound 3 is positioned
between Tyr24 and Tyr175 and forms three hydrogen bonds to
His25 in the cytidine binding pocket (one of them is a C-HNNNN
interaction similar to what is observed in serine/threonine protein
kinases [44]) and an additional hydrogen bond to Asp130
(Figure 10a). Three commercially available analogues with the
same core fragment predicted to interact with His25 but with
different substituents on the amino group were selected for testing
against EcIspE (Figure 11, Table 3). All proved less potent than the
Figure 7. Chemical structures of virtual screening hits.
doi:10.1371/journal.pone.0035792.g007
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lacking a functional group that can interact with Asp130 and the
hydroxyl group of 10 Figure 10c) is not in the right orientation
required for a hydrogen bond with this amino acid. This might
explain the loss in affinity of these ligands compared to the initial
hit.
In the modelled binding mode of ligand 4 the pyrrolopyridine
scaffold is sandwiched between Tyr24 and Tyr175 and potentially
interacts with His25 via three hydrogen bonds (Figure 12a). In
addition, the charged amino group in the tetrahydropyrimidinium
ring may form a salt bridge interaction with Asp130. Commer-
cially available analogues of this compound were selected to probe
possible interactions with Asp130, His25 and the backbone of
Lys145 (Figure 13, Table 4). Compounds 12 and 13 were chosen
because of substituents on the tetrahydropyrimidinium ring which
are likely to lower the pKa resulting in neutral compounds under
assay conditions. Accordingly, these compounds can no longer
form a salt bridge with Asp130. In the predicted binding mode of
12 a neutral hydrogen-bond via the thio-urea group is formed with
Asp130 instead while 13 is assumed to interact with Lys9 NZ and
Thr171 OG1 (Figure 12c and d). Both compounds had slightly
improved affinities compared to the screening hit suggesting that
the additional interactions may compensate for the loss of the salt
bridge. In order to accommodate 14 in the binding site in a similar
binding mode as 4, structural rearrangements are required to
avoid a steric clash of the cyclo-propyl moiety with the backbone
carbonyl group of Lys145 (Figure 2). An alternative binding mode
for this compound is also possible in which the core is flipped by
180u compared to 4 but still forms hydrogen bonds with His25
(Figure 12b). In this orientation, both substituents are solvent
exposed. Since this ligand had a 5.8-fold weaker IC50 value than
the screening hit, either of the two alternatives appear to be less
favourable than the interactions formed by the screening hit.
Compounds 15–17 carry substitutions that prevent the same
placement in the binding site with respect to His25 as suggested for
the hit compound. None of these compounds displayed any
inhibition of EcIspE even when tested up to their solubility limit (1
to 5 mM) adding confidence to the proposed binding mode of 4.
Initially, we were unable to model plausible binding modes for
the HTS hit compounds 7 and 8 (Table 2) in either the ATP or
cytidine pocket. No analogues of 7 containing an indole moiety
were present in the screening library. For compound 8,4 4
analogues with a quinazolinone core were found. Three of these
showed .40% inhibition in the initial screens but such activity was
not confirmed in the subsequent potency assay. Therefore, to
establish initial SAR further analogues of the screening hits were
identified using the similarity search method FTrees [45]. Our in-
house library of commercially available compounds was screened
using the HTS hits as query molecules and finally three analogues
of 7 and ten of 8 were purchased for biochemical evaluation.
In the case of compound 7, the analogues displayed a one to
two order loss in affinity for EcIspE (Figure 14, Table 5). Common
to all three analogues was the deletion of a hydroxyl group at R1
suggesting therefore that this group plays an important role for
Table 1. Docking ranks, physico-chemical properties, inhibition values, and ligand efficiencies for virtual screening hits.
ID Rank_total
1
MW [g/mol] clogP IC50 [M] (SD)
4 Hill slope (SD)
4






1 4849 190 0.10 1.8?10
23 (3?10
24) 1.6 (0.2) 0.33
12
(4)
2 19401 203 0.34 5.9?10
24 (3?10
25) 1.7 (0.3) 0.53
3
(2)
3 16081 199 1.92 1.6?10
24 (9?10
26) 1.0 (0.1) 0.50
13
(3)
4 74 200 1.22 1.5?10
23 (3?10
24) 1.3 (0.2) 0.32
1
(4)
5 12374 166 20.57 2.3?10
23 (6?10
25) 2.6 (0.2) 0.37
7
(3)
6 16249 149 0.67 3.5?10
23 (4?10
24) 2.2 (0.5) 0.28
7
(1)
For chemical structures see Figure 7.
1using the total score of docking for ranking (after application of the pharmacophore filter).
2using the score divided by the number of heavy atoms of the molecule for ranking (after application of the pharmacophore filter).
3setup 1: His25 protonated at ND, no ADP present; setup 2: His25 protonated at ND, ADP present; setup 3: His25 protonated at NE, no ADP present; setup 4: His25
protonated at NE, ADP present.
4average values of three independent measurements, standard deviation in brackets.
doi:10.1371/journal.pone.0035792.t001
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binding mode for the S enantiomer of this compound which is a
racemic mixture could be modelled in the cytidine pocket after
manually adjusting some side chains (RMSD=0.163 A ˚ for
relaxed side chain atoms compared to crystal structure used for
docking). In the proposed pose, the pyridinyl substituent is stacked
between the two aromatic residues in the cytidine binding site and
additionally forms hydrogen bonds with His25 while the indolyl
moiety is buried in a hydrophobic cleft (Figure 15). Further, the
hydroxyl group of R1 is involved in a hydrogen bond with Asp130.
The later interaction was already suggested to be important for
binding of inhibitors 3 and 4 (Figure 10 and Figure 12). Consistent
with this hypothesis, compounds 18 and 19, which cannot form
this interaction and, in the case of 19 would even lead to a steric
clash with Asp130, displayed markedly reduced affinity compared
to the screening hit 7. Compound 20 bears a chlorophenyl group
instead of the pyridinyl moiety and accordingly, favourable
interactions with His25 are no longer possible. This is in
agreement with the 130-fold reduced potency of this inhibitor
compared to the hit compound.
All purchased analogues of 8 proved less active than the
screening hit (Figure 16, Table 6) and no plausible binding modes
could be modelled for any of these compounds. Due to availability
issues, most of the selected compounds contain more than one
change compared to the hit compound or to each other therefore
compromising the derivation of unambiguous SAR. However, it
appears that a nitrogen atom at R1, preferably in the meta position,
Figure 9. Chemical structures of in vitro screening hits.
doi:10.1371/journal.pone.0035792.g009
Figure 8. Potency curves of compounds 3 (a), 4 (b), 7 (c) and 8 (d).
doi:10.1371/journal.pone.0035792.g008
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bromopyridinyl moiety of 8 with a methoxyphenyl group (21)i s
tolerated with a 11-fold loss in affinity. At this stage it is not
possible to say if this is due to a loss of the hydrogen-bonding
group, a steric clash or a combination of both.
Comparison of in silico and in vitro screening
Both, in silico and in vitro screening delivered two hits that were
considered worth following up. Interestingly, the virtual screening
and biochemical screening hits contained different chemical
scaffolds. Aminothiazoles (Table 3) and pyrrolopyridines
(Table 4) were only discovered using virtual screening while
biochemical screening retrieved indole derivatives (Table 5) and
quinazolinones (Table 6). The library used for HTS contained 185
aminothiazoles of which only 17 were unsubstituted in the 4-and
5-position of the thiazole moiety like the screening hit. None of
them showed significant enzyme inhibition at 33 mM in the
primary screen or could be confirmed in the secondary screen.
Attempts to model the 17 unsubstituted analogues into the
cytidine-binding pocket in a comparable binding mode to that
predicted for 3 (Figure 10a) identified the following issues: (1)
instead of an amine group some of these compounds contained an
amide group of which the carbonyl oxygen would clash with the
backbone carbonyl group of Lys145; (2) a large group attached to
the amino group of the aminothiazole core would clash with
Tyr175; (3) an acceptor functionality would be located too close to
Asp130. These observations might explain why none of the
compounds appeared as a hit in the biochemical screen. For
compound 4, only five analogues were present in the screening set.
Two of them had the pyrrolo nitrogen position blocked which is
believed to be essential for interaction with His25 (Figure 12) and
one compound did not contain a substituent which allows
interaction with Asp130. The remaining two compounds con-
tained the tetrahydropyrimidinium moiety as present in the
screening hit but again with a substitution that does not allow
interaction with Asp130. All compounds showed ,15% inhibition
at the screening concentration of 33 mM. Compounds 7 and 8
were part of the initial virtual screening library but did not pass the
first filter step as they violated the upper limit for number of heavy
atoms and ring systems. For a retrospective docking exercise we
therefore spiked the HTS library with ligands 3 and 4 docked all
compounds into all four receptor setups (Table 7). While 3 and 4
ranked highly when the database was sorted by the score
normalized for number of heavy atoms, 7 and 8 were not among
Table 2. Physico-chemical properties, inhibition values, and ligand efficiencies for in vitro screening hits.
ID MW [g/mol] clogP IC50 [M] (SD)* Hill slope (SD)*
Ligand efficiency [kcal/mol
per non-hydrogen atom]
7 329 3.63 1.9?10
25 (2?10
26) 1.4 (0.1) 0.29
8 379 2.79 2.5?10
26 (4?10
27) 1.3 (0.1) 0.35
For chemical structures see Figure 9.
*average values of three independent measurements, standard deviation in brackets.
doi:10.1371/journal.pone.0035792.t002
Figure 10. Modelled binding mode of compounds a) 3, b) 9, c) 10, and d) 11. The mesh represents the combined van der Waals radii of the
ligand atoms. The aminothiazole core is predicted to be positioned between Tyr24 and Tyr175 and to form hydrogen bonds to His25. The virtual
screening hit 3 is expected to form an additional hydrogen bond with Asp130, which none of its analogues is capable of doing.
doi:10.1371/journal.pone.0035792.g010
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did also not improve when the receptor conformation that was
manually adjusted to generate a binding mode for 7 (Figure 15)
was used for docking (data not shown).
Discussion
IspE is a potential target for new antimicrobials for a range of
pathogens [10,11,12,13,14,15]. Through a combination of virtual
and biochemical screening four new inhibitors for this enzyme
were discovered (Table 1 and Table 2). They show IC50 values of
2.5 mM( 8), 19 mM( 7), 160 mM( 3), and 1.5 mM (4), respectively
and ligand efficiencies of 0.29 kcal/mol per non-hydrogen atom or
better. The inhibitors do not resemble any previously known IspE
inhibitors (Figure 4). [16,17,18,23,24]. The physico-chemical
properties of the virtual screening hits are in the fragment-like
space (MW,300 Da, clogP#3, number of hydrogen-bond donors
#3 and hydrogen-bond acceptors #6) while those of the HTS hits
are in the lead-like space (MW,400, clogP#4, number of
hydrogen-bond donors #4 and hydrogen-bond acceptors #8)
rendering these new ligands promising starting points for drug
discovery (Figure 4).
Unfortunately, co-crystallisation of the screening hits with
AaIspE was not successful. This might be related to solubility
issues and, in the case of 8, conformational changes requiring new
crystal forms since the crystals dissolved when the compound was
added. However, for three of the four screening hits and their
analogues putative binding modes could be modelled (Figure 10,
Figure 12, and Figure 15). In the suggested binding modes, the
ligands bind into the cytidine pocket. They form p-stacking
interactions with Tyr24 and Tyr175 and hydrogen bonds with
His25 and Asp130. These binding modes are consistent with SAR
derived from analogues indicating that disrupting interactions with
His25 or Asp130 leads to a drop in binding affinity (Table 3–
Table 5, Figure 10, Figure 12, and Figure 15). However, due to
availability issues more subtle changes in the compounds could not
be probed. Therefore, SAR remains tentative. For a more
extended chemical evaluation and to increase potency synthetic
efforts around the retrieved hits are required.
We decided to adopt a virtual screening cascade with a series of
increasingly stricter filter steps (Figure 5). The aim of this strategy
was to early remove compounds that were not attractive starting
points for drug discovery and had no potential to bind to the
cytidine binding site of IspE. This made the process faster but also
easier to mange as we had to deal with a smaller number
compounds for docking. Further, molecular docking can result in
poses in which polar groups of the ligands do not form hydrogen-
bonding interactions with the receptor or vice versa and are
therefore likely to be false positive predictions [35]. These can
often be removed by using a pharmacophore to filter the docking
solutions and such improve the results [27,46]. Therefore, all
docking poses were post processed. The successful application of
similar strategies to other targets gave us confidence in this
approach [47,48]. To consider the presence and absence of the co-
factor and the potential tautomers of His25 (Figure 6), four
different setups for docking were prepared. While compounds
from all setups were chosen for testing, for the most promising hit
compounds (3 and 4) only one of the possible tautomers for His25
was found to be important (Table 1). In this representation, a
protonated NE of His25 is required, which is different from the
substrate-bound state of the pocket (Figure 2). Coincidently, this is
the same tautomer that was used for modelling the binding mode
of the biochemical screening hit 7 (Figure 15). The virtual
screening library contained a mix of fragment- and lead-like
compounds. To favour compounds that were predicted to bind
with high ligand efficiency we normalized the scores by the
number of heavy atoms. Both, compounds with a high total score
and a high normalized score were carried forward for visual
inspection. Interestingly, all compounds that showed any IspE
inhibition (Table 1) were selected based on the latter criteria and
were in the fragment-like space making this exercise yet another
success story of fragment-based virtual screening
[25,47,48,49,50,51,52].
In silico and in vitro screening retrieved chemically distinct hits.
(Table 1 and Table 2). On the basis of structural considerations
and for reasons of cost efficiency, it was decided to use a small,
focussed library containing about 6,000 compounds for in vitro
screening. Despite the limited size, the scaffolds of both virtual
screening hits were contained in this library. With just five
examples, chemical space around hit 4 was poorly represented. It
is therefore unsurprising, that this compound class was not
retrieved using in vitro screening. In contrast, 185 compounds
containing aminothiazoles were part of the screening library yet
this compound class did not appear among the HTS hits. A reason
for this might be that only 17 aminothiazoles were unsubstituted in
Figure 11. Chemical structures for analogues of ligand 3.
doi:10.1371/journal.pone.0035792.g011
Table 3. Hit expansion for ligand 3.
ID IC50 [M] (SD)* Hill slope (SD)* Ligand efficiency [kcal/mol per non-hydrogen atom]
3 1.6?10
24 (9?10
26) 1.0 (0.1) 0.50
9 9.4?10
23 (2?10
23) 1.4 (0.0) 0.30
10 6.6?10
23 (2?10
24) 1.1 (0.2) 0.27
11 2.0?10
23 (4?10
24) 1.1 (0.4) 0.50
For chemical structures see Figure 11.
*average values of three independent measurements, standard deviation in brackets.
doi:10.1371/journal.pone.0035792.t003
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additional functionalities that were predicted to lead to a steric
clash in the binding site and/or unfavourable interactions with
Asp130. It is an on-going debate as to how many analogues should
be contained in a screening library to have a good chance to
discover a hit. Often, 50–100 analogues are considered sufficient
[40,53,54]. Clearly, that was not the case in our investigation.
Given the appropriate infrastructure, large libraries can be
screened in silico in a cost efficient manner, overcoming a problem
with in vitro screening of having to preselect library compounds and
thus to restrict commercially available chemical space. However, it
is well known that docking performance decreases with increasing
molecular size and number of rotational bonds [55,56,57].
Therefore, the complexity of the compounds in the in silico library
was limited (Figure 5). As a consequence, the HTS hits 7 and 8
were rejected as they violated the upper limit of number of heavy
atoms (not more than 23) and ring systems (not more than two).
Even if the HTS library had been used for virtual screening, 7 and
8 could not have been discovered (Table 7). Both compounds
ranked poorly when docking this library against IspE and more
promising compounds like 3 and 4 would still have been favoured
for biochemical testing. It remains unclear which binding mode 8
adopts when binding to IspE and therefore why docking failed. In
contrast, we speculated that binding of 7 requires a conforma-
tional change of the receptor (Figure 15). When this receptor
conformation was used for docking, a more sensible binding mode
was obtained but ranking was still poor. This points to a limitations
of molecular docking: While progress has been made in
considering receptor flexibility in practice, it is still often neglected
when screening large databases due to speed issues, scoring
problems and difficulties in predicting relevant protein conforma-
tions [58]. As a result, ligands that require a conformational
change of the receptor in order to bind will not be retrieved.
Furthermore, fragment hits are often weaker ligands than the
larger HTS hits [25]. This was also the case here. While the HTS
hits showed affinities in the low micromolar range, the virtual
screening hits were less potent with IC50 values in the high
micromolar to low millimolar range (Table 1 and Table 2).
However, the ligand efficiencies of the virtual screening hits were
comparable or higher than those of the HTS hits. Assuming that
the ligand efficiency stays approximately constant during optimi-
sation [59], despite their weaker potencies the virtual screening
hits are therefore at least as good starting points for a hit-to-lead
program as are the HTS hits. A benefit of the virtual screening hits
was that they came immediately with a hypothesis about which
binding mode they might adopt. This allowed rational selection of
analogues to probe the binding mode and derive SAR. In contrast,
for one of the HTS hits (7) a binding mode could only be suggested
after derivatives selected using ligand-based similarity screening
were tested. For inhibitor 8, even this approach did not lead to a
binding hypothesis. Finally, retrieval of the virtual screening hits
was a prerequisite to conduct a robust HTS. Since none of the
standard kinase inhibitors turned out to be active against IspE and
previously known IspE inhibitors were not commercially available,
the virtual screening hits served as quality control standards for
biochemical screening ensuring that our screening results were
reliable [60].
Conclusions
The DOXP pathway is an essential aspect of metabolism and a
validated target for antimicrobials for a range of pathogens. A
combination of in silico and in vitro screening against IspE, the
fourth enzyme in this pathway, has identified non-substrate like
inhibitors. The two strategies were complementary, delivering
chemical distinct hits. However, running a robust and reliable
biochemical screening campaign only became possible after the
Figure 12. Modelled binding modes of compounds a) 4, b) 14, c) 12, and d) 13. The mesh represents the combined van der Waals radii of
the ligand atoms. The pyrrolopyridine scaffold is predicted to be sandwiched between Try24 and Tyr175 and to form hydrogen bonds with His25. The
virtual screening hit 4 is expected to form an additional salt bridge with Asp130 while. 12 is expected to form hydrogen bonds with Lys9 and Thr191
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available inhibitors for IspE which could serve as quality control
standard were known. Four of the identified hits were followed-up
with analogues. While most of the commercially available
analogues were less potent than the screening hits, they allowed
SAR to be established and identification of crucial amino acids for
ligand binding. The new inhibitors possess favourable physico-
chemical properties and good ligand efficiencies. They therefore
constitute promising starting points for further optimization.
Methods
Computational methods
Figures of protein-ligand complexes were prepared using PyMol
(Open-Source PyMOL 0.99rc6, Copyright 2006, DeLano Scien-
tific LLC).
Structure-based virtual screening. Our in-house MySQL
library of commercially available compounds [40] was filtered for
compounds fulfilling the following criteria: between one and five
hydrogen-bond donors, one and ten hydrogen-bond acceptors,
between nine and 23 heavy atoms, clogP between 21 and 4, less
than seven rotatable bonds, total charge between 21 and +1, and
one or two ring systems (fused rings were counted as one ring
Figure 13. Chemical structures for analogues of ligand 4.
doi:10.1371/journal.pone.0035792.g013
Table 4. Hit expansion for ligand 4.
ID IC50 [M] (SD)* Hill slope (SD)* Ligand efficiency [kcal/mol per non-hydrogen atom]
4 1.5?10
23 (3?10
24) 1.3 (0.2) 0.32
12 8.3?10
24 (7?10
25) 1.0 (0.1) 0.27
13 4.7?10
24 (1?10
24) 1.0 (0.1) 0.26
14 8.7?10
23 (4?10




17 n.i. - -
For chemical structures see Figure 13.
*average values of three independent measurements, standard deviation in brackets.
ano inhibition at solubility limit measured.
doi:10.1371/journal.pone.0035792.t004
Figure 14. Chemical structures for analogues of ligand 7.
doi:10.1371/journal.pone.0035792.g014
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toxic functionalities [40] were rejected.
Unity from the Sybyl package (Tripos A. St. Louis, MO, U.S.A)
was used for pharmacophore filtering. Pharmacophoric points
were defined protein based (Protein Data Bank (PDB) code 2v8p)
with default settings to include the desired directionalities for
hydrogen bonding. The initial pharmacophore search was
performed with flexible ligand molecules, allowing rotation and
conformational changes to match the required features. At least
two of the possible four features had to be fulfilled to pass this filter.
For filtering the docking poses, the docked ligands were kept rigid
and no translations and rotations were allowed.
A database containing all compounds passing the pharmaco-
phore filter step in a format suitable for docking and considering
multiple protonation states and tautomers was prepared as
described previously [47].
The AaIspE crystal structure (PDB code 2v8p) was the receptor
for docking. Four different setups were prepared taking into
account the possible tautomers of His25 (Figure 6), and the
presence or absence of the co-factor. Polar hydrogen atoms were
added to the receptor and their positions minimised using the
MAB force field [61] as implemented in MOLOC (Gerber
Molecular Design: Switzerland). Partial charges for the co-factor
were calculated using AMSOL [62]. Spheres as matching points
for docking were placed around the cytidine heterocycle of the
bound substrate. The sphere set defining the buried region of the
binding site was generated around the whole substrate and co-
Table 5. Hit expansion for ligand 7.
ID IC50 [M] (SD)* Hill slope (SD)* Ligand efficiency [kcal/mol per non-hydrogen atom]
7 1.9?10
25 (2?10
26) 1.4 (0.1) 0.29
18 5.5?10
24 (5?10
28) 0.8 (0.0) 0.21
19 2.4?10
23 (4?10
24) 0.8 (0.1) 0.18
20 2.5?10
23 (3?10
24) 1.1 (0.1) 0.18
For chemical structures see Figure 14.
*average values of three independent measurements, standard deviation in brackets.
doi:10.1371/journal.pone.0035792.t005
Figure 15. Modelled binding mode of compound 7. The mesh
represents the combined van der Waals radii of the ligand atoms. In this
orientation the pyridinyl group is stacked between Tyr24 and Tyr175
and forms hydrogen bonds with His25. Further, the hydroxyl group
forms a hydrogen bond with Asp130 while the indolyl moiety is buried
in a hydrophobic cleft.
doi:10.1371/journal.pone.0035792.g015
Figure 16. Chemical structures for analogues of ligand 8.
doi:10.1371/journal.pone.0035792.g016
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excluded volumes, electrostatic and van der Waals potential, and
solvent occlusion were calculated as described earlier [31]. DOCK
3.5.54 [63,64] was used to dock the molecules into the binding
sites. The following settings were chosen to sample ligand
orientations: ligand and receptor bins were set to 0.5 A ˚, and
overlap bins were set to 0.4 A ˚; and the distance tolerance for
matching ligand atoms to receptor matching sites ranged from 1.1
to 1.2 A ˚. Each docking pose which did not place any atoms in
areas occupied by the receptor was scored for electrostatic and van
der Waals complementarity and penalised according to its
estimated partial desolvation energy [65]. The docking setup
was validated by successful predictions of the binding modes of
CDP, CDP-ME, and cytosine (data not shown). For each
compound in the screening database, only the best-scoring
representation (tautomer, protonation state, multiple ring align-
ment) was stored in the final docking hit list.
Manual modelling of binding modes. The binding mode
for compound 7 was modelled manually using MOLOC. The
ligand was placed in possible orientations in the binding site and
the positions were minimised allowing side chains to relax while
backbone atoms were kept rigid. The most convincing mode was
selected based on complementarity of functional groups between
ligand and receptor and the avoidance of van der Waals clashes as
well as accordance with the SAR hypothesis of this compound
series.
For analogues of compounds 3 and 4, the core fragment was
initially superposed on the docking poses of the parent
compounds. Manual adjustment of additional functional groups
was followed by minimization with the MAB force field as
implemented in MOLOC whereas the ligand was kept flexible and
the binding pocket rigid.
Feature Trees search. Molecular similarity searches were
performed with the program Feature Trees, version 2 (BiosolveIT,
Germany) [45]. Compounds 7 and 8 were used as query
molecules. The ligands were pre-processed with Sybyl as follows:
atom types and formal charges were assigned, hydrogen atoms
were added, 3D structures were generated and energy minimised.
Our in-house compound database [40] was converted to Feature
Trees and used for searching similar compounds to the query
molecules. Similarity values between the database compounds and
the query molecules at ‘‘level 0’’ (global similarity considering all
features in each Feature Tree at once) and similarity values at
‘‘level x’’ (best similarity of two Feature Trees after a recursive
comparison algorithms has been used) were calculated using the
match search algorithm. Default values were assigned to all
adjustable parameters. Hits with a similarity value of above 0.95
were inspected to shortlist compounds for purchase and testing.
Biochemical methods
Protein preparation. Recombinant EcIspE was purified
following published methods [18,19]. For each batch of enzyme
the kinetic constants KM and kcat were determined using an
established assay [18] and compared with published data as a
quality control measure.
Table 6. Hit expansion for ligand 8.
ID IC50 [M] (SD)* Hill slope (SD)* Ligand efficiency [kcal/mol per non-hydrogen atom]
8 2.5?10
26 (4?10
27) 1.3 (0.1) 0.35
21 2.7?10
25 (9?10
26) 1.1 (0.3) 0.28
22 1.8?10
24 (4?10
25) 0.8 (0.1) 0.26
23 3.2?10
24 (8?10
25) 0.7 (0.1) 0.23
24 n.i.
a --
25 n.i. - -
26 n.i. - -
27 n.i. - -
28 n.i. - -
29 n.i. - -
30 n.i. - -
For chemical structures see Figure 16.
*average values of three independent measurements, standard deviation in brackets.
ano inhibition at solubility limit measured.
doi:10.1371/journal.pone.0035792.t006
Table 7. Ranks for the in silico and in vitro screening hits
when the HTS library is docked against AaIspE without prior
















For chemical structures see Figure 7 and Figure 9.
1using the total score of docking for ranking.
2using the score divided by the number of heavy atoms of the molecule for
ranking.
3setup 1: His25 protonated at ND, no ADP present; setup 2: His25 protonated at
ND, ADP present; setup 3: His25 protonated at NE, no ADP present; setup 4:
His25 protonated at NE, ADP present.
doi:10.1371/journal.pone.0035792.t007
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using the Promega Kinase-GloH-Plus kit [66]. This kit determines
the remaining ATP concentration after the kinase reaction took
place by converting luciferin to oxyluciferin via an ATP-dependent
luciferase. Oxyluciferin is chemoluminescent and can be detected
using a plate reader.
The assay was performed under the following conditions:
90 mM ATP, 500 mM CDP-ME, 200 nM EcIspE in 100 mM Tris-
HCl, pH 8.5, 20 mM MgCl2, 2% DMSO, 0.01% (v/v) Triton-X
100. The reaction was carried out in 384-well plates with 25 ml
reaction volumes, incubated at 25uC for 180 min, and stopped
with 25 ml Kinase-GloH Plus reagent (Promega, Madison, USA).
The chemoluminescence signal was developed for 45 min at room
temperature and read out in a plate reader (TopCount,
PerkinElmer, USA). To monitor assay performance and to control
for inhibition of the luciferase of the Kinase-GloH Plus kit wells
containing either the reaction mixture plus compound 3 or 4 or all
ingredients except for CDP-ME were also prepared. Further, as
quality control for each assay plate, wells containing the kinase
reaction without an inhibitor, and wells containing only ATP in
assay buffer were prepared. The signals of these wells were
averaged (AVHIGH,A V LOW) and used to calculate the signal to




SD: standard deviation). The best performance was obtained with
an ATP concentration of 90 mM and a CDP-ME concentration of
500 mM (Signal to noise ratio=3.3, Z9=0.69 in assay develop-
ment). In this setup the ATP and CDP-ME concentrations are
,0.26KM and ,36KM, respectively [16]. Consequently, the assay
can be used to detect ligands binding to both the substrate and co-
factor binding sites.
IC50 determinations and ligand efficiencies. Compound
1 was ordered from Maybridge (Fisher Scientific UK Ltd,
Leicestershire, UK), compounds 2 and 3 from ChemDiv (San
Diego, USA), compounds 4, 7, 9, 11, 12, 13 from Enamine Ltd.
(Kiev, Ukraine), compounds 5 and 6 from Sigma-Aldrich Chemie
GmbH (Munich, Germany), compound 8 from TimTec LLC
(Newark, USA), compounds 10, 14, 16, 17 from Asinex Ltd.
(Moscow, Russia), compound 15 from Bionet (Key Organics,
Cornwall, UK), compounds 18, 19, 20 from Princeton
BioMolecular Research Inc. (NJ, USA), compound 21 from
ChemBridge Corporation (San Diego, USA), and compounds 22
and 23 from Aurora Fine Chemicals LLC (San Diego, USA).
Identity and purity of key compounds (3, 4, 7–14, 18, 19, and
21) were analysed by LC-MS using a Bruker MicroTof mass
spectrometer coupled to an Agilent HPLC 1100, with a diode
array detector in series. The column used was a Phenomenex
Gemini C18 column, 5063.0 mm, 5 mm particle size. The
following method was used: mobile phase, water/acetoni-
trile+0.1% HCOOH 80:20 to 5:95 gradient over 3.5 min, and
then held at for 1.5 min; flow rate 0.5 mL/min. All investigated
compounds had the correct identity judged by the M+ data.
Compound 12 was 70% pure, compounds 4, 7, 8, 19 and 21
between 81 and 86% and the remaining compounds .95%.
Compounds were dissolved in DMSO at concentrations
between 10 and 200 mM (depending on maximal solubility) and
added to the reaction mixture with a final concentration of 2%
DMSO (v/v). For compounds where IspE inhibition was
indicated, a 1:3 dilution series in DMSO was prepared and tested
in the same endpoint assay. IC50 values were derived by non-linear
regression with a 4-parameter fit to the following equation in
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where y: measured signal of assay: ymax: saturated signal: [I]:
inhibitor concentration: slope: Hill slope; ymin: background signal
of assay.
As the assay was performed at relatively high substrate
concentrations (,36KM) for ligand efficiency calculations [39],
the measured IC50 values were first converted to Ki values.
Assuming competitive inhibition of the cytidine binding site the






where KM is 150 mM and [CPD-ME]=500 mM [16].
Ligand efficiencies were calculated using the formula:
LE~
{RT lnKi
number of heavy atoms
where T=298 K and R=the ideal gas constant.
In vitro screening of the kinase library. Compounds from
the kinase set, stored as 3.3 mM stock solutions in DMSO, were
dispensed into black 384 well assay plates (Thermo Scientific
Matrix,) using a HummingBird
TM (Cartesian,) with a 250 nl
dispenser head. 15 ml of the enzyme- and substrate solution were
dispensed into each well with a PlateMate Plus (Thermo Scientific
Matrix,). The reaction was started with 10 ml ATP solution
dispensed by a WellMate robot (Thermo Scientific Matrix,).
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